Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. LYN and CYBB are pivotal immune and inflammatory genes as diagnostic biomarkers in recurrent spontaneous abortion.Frontiers in immunology · 2025
   Article
2. Two Enhances the Cisplatin Sensitivity of Cervical Cancer Cells via Suppression of c-MET Expression.Iranian journal of public health · 2023
   Article
3. Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment.Frontiers in oncology · 2023
   Article
4. Molecular Endoscopy for the Diagnosis and Therapeutic Monitoring of Colorectal Cancer.Frontiers in oncology · 2022
   Review
5. MiR-300 Alleviates Cell Proliferation and Migration and Facilitates Cell Apoptosis by Targeting c-Met in Gastric Cancer.Journal of oncology · 2022
   Article
6. An Inflammatory Response-Related Gene Signature Reveals Distinct Survival Outcome and Tumor Microenvironment Characterization in Pancreatic Cancer.Frontiers in molecular biosciences · 2022
   Article
7. CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways.Oncotarget · 2021
   Article
8. C1GALT1 in health and disease.Oncology letters · 2021
   Review
9. A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment.MedComm · 2020
   Article
10. HGF/c-Met Axis: The Advanced Development in Digestive System Cancer.Frontiers in cell and developmental biology · 2020
    Review
11. New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment.Biomedicines · 2018
    Review

Corrections and comments

• Erratum for
  Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.2017

Authors and funding

11 authors.

Funding

Abstract